Oncotarget

Research Papers:

Focused ultrasound enhanced molecular imaging and gene therapy for multifusion reporter gene in glioma-bearing rat model

Feng-Yi Yang _, Wen-Yuan Chang, Wei-Ting Lin, Jeng-Jong Hwang, Yi-Chun Chien, Hsin-Ell Wang and Min-Lan Tsai

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:36260-36268. https://doi.org/10.18632/oncotarget.5389

Metrics: PDF 877 views  |   HTML 1645 views  |   ?  


Abstract

Feng-Yi Yang1,2, Wen-Yuan Chang1, Wei-Ting Lin1, Jeng-Jong Hwang1, Yi-Chun Chien1, Hsin-Ell Wang1, Min-Lan Tsai3

1Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan

2Biophotonics and Molecular Imaging Research Center, National Yang-Ming University, Taipei, Taiwan

3Department of Pediatrics, Cheng Hsin General Hospital, Taipei, Taiwan

Correspondence to:

Feng-Yi Yang, e-mail: fyyang@ym.edu.tw

Jeng-Jong Hwang, e-mail: jjhwang@ym.edu.tw

Keywords: focused ultrasound, molecular imaging, gene therapy, blood-brain barrier, brain tumor

Received: July 11, 2015     Accepted: September 14, 2015     Published: September 25, 2015

ABSTRACT

The ability to monitor the responses of and inhibit the growth of brain tumors during gene therapy has been severely limited due to the blood-brain barrier (BBB). A previous study has demonstrated the feasibility of noninvasive in vivo imaging with 123I-2’-fluoro-2’-deoxy-5-iodo-1-β-D-arabinofuranosyluracil (123I-FIAU) for monitoring herpes simplex virus type 1 thymidine kinase (HSV1-tk) cancer gene expression in an experimental animal model. Here, we tested the enhancement of SPECT with 123I-FIAU and ganciclovir (GCV) treatment in brain tumors after BBB disruption induced by focused ultrasound (FUS) in the presence of microbubbles. We established an orthotopic F98 glioma-bearing rat model with trifusion reporter genes. The results of this study showed that the rat model of HSV1-tk-expressing glioma cells could be successfully detected by SPECT imaging after FUS-induced BBB disruption on day 10 after implantation. Compared to the control group, animals receiving the GCV with or without sonication exhibited a significant antitumor activity (P < 0.05) of glioma cells on day 16 after implantation. Moreover, combining sonication with GCV significantly inhibited tumor growth compared with GCV alone. This study demonstrated that FUS may be used to deliver a wide variety of theranostic agents to the brain for molecular imaging and gene therapy in brain diseases.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5389